COVARIATE-DEPENDENT STRUCTURES 131
Modeling Σ as a function of covariates using the GARP/IV parameters
Recall that the GARP, {φ
ijk
},areunconstrained,asarethelogof the inno-
vation variances {log(σ
2
ij
)}.Covariatescan therefore be introduced as
φ
ijk
= v
ijk
γ, k =1,...,j− 1,j=2,...,J,
log(σ
2
ij
)=d
ij
λ, j =1,...,J,
where v
ijk
and d
ij
are design matrices for the GARP and log innovation
variances, respectively. These design vectorscontaincovariates of interest.
The form of these models is the same as the structured GARP/IV models,
but now the design vectors are also indexed by i and include covariates.
We again illustrate this approach using thedata from the schizophrenia
clinical trial (described in Section 1.2). The main covariate of interest in this
data was treatment, so we examine the GARP and IV parameters by treat-
ment. Figure 6.4 shows the posterior means of the log innovation variances
for each treatment. Within each treatment, the innovation variances do not
show much structure as a function of time. However, there appear to be some
large differences across treatments. For example, the innovation variances for
the high dose at weeks4and6are considerably higher than for the other
three treatments. These plots suggest that the innovation variances at weeks
4and6couldbemodeled as a function of treatment.
Figure 6.5 shows the lag-1 GARP for each treatment, again plotted as a
function of time. Here, the lag-1 GARP at week 6 for the medium dose is
much smaller than for the other three treatments (with its credible interval
not overlapping with the standard dose treatment) and we could allow this
GARP to differ by treatment.
This exploratory analysis suggests the covariance matrix for the schizophre-
nia data does depend on treatment, and the GARP/IV parameterization pro-
vides a parsimonious way to model this as the individual parameters can de-
pend (or not) on (a subset of) treatment groups and the resulting covariance
matrices will be guaranteed to be positive definite.
These GARP/IV models will be explored more formally for the Growth
Hormone data in Chapter 7. For a detailed application of these models, see
Pourahmadi and Daniels (2002).
The modified Cholesky parameterization has also been used to introduce
covariates into the random effects covariance matrix in the normal random
effects model (Example 2.1) (Daniels and Zhao, 2003) and could also be used
for the random effects covariance matrixingeneralized linear mixed models
(Example 2.2); however, there should be some implicit or explicit ordering of
the random effects for this parameterization to be fully justified because the
parameterization is not invariant to the ordering of the components of b
i
.Ifthe
components of b
i
were the coefficients of orthogonal polynomials or regression
splines, there is an obvious ordering. For a detailed example of introducing